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The AMP-activated protein kinase (AMPK) is an abg
heterotrimer that plays a pivotal role in regulating
cellular and whole-body metabolism. Activation of
AMPK reverses many of the metabolic defects asso-
ciatedwith obesity and type 2diabetes, and therefore
AMPK is considered a promising target for drugs to
treat these diseases. Recently, the thienopyridone
A769662 has been reported to directly activate
AMPK by an unexpected mechanism. Here we show
that A769662 activates AMPK by a mechanism in-
volving the b subunit carbohydrate-binding module
and residues from the g subunit but not the AMP-
binding sites. Furthermore, A769662 exclusively acti-
vates AMPK heterotrimers containing the b1 subunit.
Our findings highlight the regulatory role played by
the b subunit in modulating AMPK activity and the
possibility of developing isoform specific therapeutic
activators of this important metabolic regulator.
INTRODUCTION
The AMP-activated protein kinase (AMPK) is a key regulator of
cellular and whole-body energy balances that coordinates me-
tabolism in response to changes in energy supply and demand.
At the cellular level, AMPK protects against stresses that lower
energy charge by switching metabolism in favor of ATP produc-
tion while inhibiting ATP consumption. AMPK regulates virtually
every branch of cellular metabolism including fatty acid and
sterol synthesis, lipid oxidation, protein synthesis, and carbohy-
drate metabolism. It has also become evident that AMPK plays
a pivotal role in regulating whole-body energy homeostasis,
integrating hormonal and nutritional signals in multiple tissues
to regulate food intake and body weight.
AMPK functions as a heterotrimer comprising an a catalytic
subunit and regulatory b and g subunits. The a subunit consists
of an N-terminal catalytic domain and a C-terminal domain in-
volved in complex formation (Crute et al., 1998). The conserved
C-terminal domain of the b subunit functions as a scaffold bind-
ing the a and g subunits (Iseli et al., 2005; Townley and Shapiro,1220 Chemistry & Biology 15, 1220–1230, November 24, 2008 ª2002007). The b subunits also contain an internal carbohydrate-
binding module (CBM; previously termed GBD) that is similar
to domains found in other carbohydrate-binding proteins such
as glycogen branching enzyme and isoamylase (Hudson et al.,
2003; Polekhina et al., 2003). The CBM serves to associate
AMPK complexes with glycogen particles in vitro and in intact
cells; however, the functional significance of this interaction
remains poorly understood. The g subunits of AMPK contain
four tandem repeats of a sequence known as CBS motifs that
function in pairs to form discrete structural units termed Bate-
man domains, which are the allosteric binding sites for AMP
and ATP (Scott et al., 2004). AMPK is principally activated by
phosphorylation of Thr172 within the activation loop of the a cat-
alytic domain by multiple protein kinases including LKB1, Ca2+/
calmodulin-dependent protein kinase kinase b (CaMKKb), and
possibly transforming growth factor b kinase (TAK1) (reviewed
in Hardie, 2007). Binding of AMP to the g subunits activates
AMPK by two distinct mechanisms involving direct allosteric
activation and inhibition of dephosphorylation by protein phos-
phatases (Sanders et al., 2007b).
Activation of AMPK in vivo elicits a number of metabolic re-
sponses that would be expected to counteract the physiological
abnormalities associated with obesity and type 2 diabetes, and
consequently AMPK is regarded as one of the most promising tar-
gets for new drugs to tackle the growing epidemic of metabolic
diseases. As proof of concept, pharmacological activation of
AMPK withAICAR (which is converted incells to the AMPmimetic,
ZMP) in animal models of insulin resistance reverses many of the
hallmarks indicative of the metabolic syndrome (Bergeron et al.,
2001; Song et al., 2002). Moreover, AMPK is activated indirectly
by two classes of glucose-lowering drugs, the biguanides and
thiazolidindiones, which are prescribed worldwide (Fryer et al.,
2002; Zhou et al., 2001). As part of ongoing efforts to identify
new activators of AMPK, it was reported that a small-molecule
thienopyridone, A769662, directly activates AMPK (Cool et al.,
2006). Two recent studies demonstrated that A769662 mimics
both effects of AMP on the AMPK system but via an AMP-
independent mechanism, suggesting that A769662 binds to an
alternate allosteric site (Goransson et al., 2007; Sanders et al.,
2007a). Furthermore, the b subunit and in particular Ser108 within
the CBM, but not the glycogen-binding site, were found to be crit-
ical for activation. Despite these advances in our understanding,
the binding site for A769662 remains to be elucidated.8 Elsevier Ltd All rights reserved
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Regulation of AMPKFigure 1. The b1 Subunit Carbohydrate-Binding Module Is Essential
for Activation by A769662
(A) The effect of b1 subunit myristoylation on activation of AMPK by A769662
was determined using the nonmyristoylated b1 G2A mutant. AMPK activity
was measured using the SAMS assay in the absence or presence of either
20 mM A769662 or 100 mM AMP and shown as the mean ± SEM for duplicate
experiments.Chemistry & Biology 15, 1220–1In the present study, we have investigated the activation of
AMPK by A769662 using recombinant enzyme preparations
and intact cells derived from wild-type and AMPK b1 null mice
in order to gain further insights into its mechanism of action
and its effects on cellular metabolism. We report that activation
by A769662 involves an interaction between the b subunit
CBM and residues from the g subunit that are not involved in
AMP binding. Unexpectedly, we found that A769662 exclusively
activates AMPK complexes containing the b1 subunit isoform
and, using hepatocytes generated from AMPK b1 null mice,
found that the glucose-lowering effect of A769662 in these cells
occurs independently of AMPK activation.
RESULTS
Defining the Region of the b1 Subunit Required
for Activation by A769662
Previous studies showed that an AMPK complex lacking resi-
dues 1–185 of the b1 subunit is no longer activated by
A769662, suggesting that either the uncharacterized N-terminal
region of the b subunit, the CBM, or both are required for activa-
tion (Sanders et al., 2007a). The N-terminal extension of the b1
subunit is myristoylated on Gly2, and removal of the myristoyl
group by point mutation activates AMPK (Warden et al., 2001);
therefore, we initially investigated whether A769662 activates
AMPK by a mechanism involving relieving inhibition caused by
myristoylation. Figure 1A shows that the Gly2Ala mutant has
approximately 4-fold increased basal activity compared with
wild-type but is still activated by A769662 and AMP. These
findings demonstrate that A769662 actions are independent of
b1 myristoylation. Next, we generated a series of N-terminal de-
letions to more accurately define the region of the b1 subunit that
is required for activation by A769662. Deletions were generated
by PCR and coexpressed with GST-a1 and g1 subunits in COS7
cells. Protein was corrected for expression by immunoblotting
with an anti-a1 antibody and densitometry. We also used a
monoclonal C-terminal b1 antibody to confirm that all trunca-
tions were successfully expressed (Figure 1B). Truncation of
the first 64 residues substantially increased basal activity, but
A769662-mediated activation was unaffected. Further deletions
removing either half or the complete CBM abolished the effect of
the drug (Figure 1C). Although deletion of the b1 residues 1–63
caused substantial activation, this effect was not retained in
further C-terminal deletions (125–270 and 146–270).
A769662 Does Not Bind Directly
to the Carbohydrate-Binding Module
Given that the CBM is necessary for activation by A769662, we
speculated that A769662 might bind to a novel binding site on
(B) Analysis of expression of b1 truncated complexes by western blot. Ten
microliters of AMPK immobilized on glutathione-Sepharose beads was sepa-
rated on SDS-PAGE. Membranes were probed with rabbit polyclonal anti-a1
and rabbit monoclonal anti-b1 antibodies, and protein was detected using pro-
tein G-coupled horseradish peroxidase and enhanced chemiluminescence.
(C) The effect of b1 subunit deletions on activation of AMPK was measured
using the SAMS assay in the absence or presence of either 20 mM A769662
or 100 mM AMP and results are shown as the mean ± SEM for duplicate exper-
iments. * denotes significantly different from control (p < 0.05). y denotes
significantly different from wild-type control (p < 0.02).230, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1221
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plored this possibility using nuclear magnetic resonance (NMR)
spectroscopy, which has been used previously to study the
nature of sugar binding to the carbohydrate-binding site (Koay
et al., 2007). A number of 1H-15N HSQC spectra were collected
using labeled b1-CBM (0.2 mM) in the presence and absence
of either 10 mM maltoheptaose or 5 mM A769662 in order to de-
termine binding. Under these conditions, we detected significant
changes in the chemical shift pattern in the presence of malto-
heptaose (Figure 2A), such as Lys126 known to be involved in
sugar binding from the crystal structure (Polekhina et al.,
2005); however, there were negligible changes in the chemical
shift distribution after the addition of A769662 (Figure 2B). Based
on these results, we conclude that the CBM alone does not
contain the A769662-binding site.
Identification of Residues in the g Subunit Involved
in Activation by A769662
In order to further understand the molecular mechanism of acti-
vation by A769662, we next investigated whether other regions
of the AMPK complex in close proximity to the CBM influence
A769662 activation. The crystal structure of the core fragment
of the Saccharomyces cerevisiae AMPK ortholog (Protein Data
Bank ID code 2QLV) shows a direct interaction between the
carbohydrate-binding loop of the CBM and the g subunit helix
a2B (Amodeo et al., 2007). We therefore investigated whether
residues from the g subunit that are predicted to interact with
the b1-CBM modulate A769662 activation. Because the crystal
structure of the mammalian abg core complex does not include
the CBM, we constructed a homology model for this region
based on the mammalian heterotrimer using the S. cerevisiae
structure as a template for positioning the CBM, and the resulting
model for b1:CBM/b1:190–272/g1:23–326 is shown in Figure 3A.
Three residues (Phe175, Leu178, and Phe179) in helix a2B of g1
form a hydrophobic patch, which is positioned to interact with
the sugar-binding loop from b1-CBM (Figure 3B). In addition,
g1-Arg171 is positioned to enable hydrogen bonding with back-
Figure 2. The Carbohydrate-Binding Mod-
ule Is Not Sufficient to Bind A769662
(A) Overlayed two-dimensional 1H-15N HSQC
spectra showing chemical shift changes in the
nuclei of b1-CBM after the addition of 10 mM
maltoheptaose. Labeled residues are those that
showed significant chemical shift upon titration
of ligand.
(B) Same as (A), except spectra were collected in
the absence and presence of 5 mM A769662.
bone Ser144 and Gln145 oxygens within
the b1-CBM. Because A769662 is rela-
tively lipophilic by virtue of the two aro-
matic rings attached to its thienopyridone
core, this prompted us to investigate
whether the g1 residues that form this hy-
drophobic patch influence activation by
the drug. We therefore generated a series
of g1 point mutants (Arg171Gln, Phe175-
Tyr, Phe175Leu, Leu178Ala, Phe179Tyr,
and Phe179Leu) that were coexpressed with GST-a1 and b1 in
COS7 cells. Expression levels were assessed by western blot
using an anti-a1 antibody, and protein levels were corrected
for differences in expression by densitometry. Several studies
have shown that mutation of residues in the AMP-binding sites
render AMPK insensitive to the stimulatory effects of AMP while
at the same time increasing basal activity in the absence of AMP
(Burwinkel et al., 2005; Hamilton et al., 2001). We therefore
initially tested the effect of the g1 mutants on basal activity and
the Thr172 phosphorylation status independently of any effect
on allosteric activation. Figure 4A shows that the Phe175Tyr,
Phe175Leu, and Phe179Tyr mutations increased phosphoryla-
tion of Thr172 and AMPK activity. In contrast, the Leu178Ala
and Phe179Leu mutations reduced Thr172 phosphorylation
and reduced AMPK activity, whereas Arg171Gln had no effect
on basal phosphorylation (Figure 4A). We next measured alloste-
ric activation of the g1 mutants with either A769662 or AMP and
found that all the mutants could be activated with either agonist
to varying extents. The Phe175Tyr, Phe175Leu, and Phe179Tyr
mutants all had reduced allosteric activation by both A769662
and AMP, whereas the Leu178Ala and Phe179Leu mutants
had a similar fold activation to wild-type AMPK (Figure 4B).
Although the Arg171Gln mutant had a similar activation with
A769662 as wild-type enzyme, it had reduced stimulation with
AMP. As it was apparent that the g1 mutants with increased
basal phosphorylation had reduced allosteric activation, we de-
cided to measure allosteric activation of the AMPK a1b1g1 com-
plex at various time points after phosphorylation with CaMKKb.
Figure 4C shows that phosphorylation of AMPK with CaMKKb
for longer than 10 min causes a decrease in the ability of both
A769662 and AMP to allosterically activate AMPK. This suggests
that a higher degree of phosphorylation of AMPK is important in
regulating sensitivity to allosteric activation; therefore, in order to
study activation of the g1 mutants by A769662 and AMP inde-
pendently of their different phosphorylation states, the mutants
were first dephosphorylated with l phosphatase for 60 min
and then reactivated with CaMKKb for 10 min in order to obtain1222 Chemistry & Biology 15, 1220–1230, November 24, 2008 ª2008 Elsevier Ltd All rights reserved
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the activators (Figure 4D). Dephosphorylation and reactivation
with CaMKKb restores the A769662 and AMP dependence of
the Phe175Tyr, Phe175Leu, and Phe179Tyr mutants to similar
levels as wild-type AMPK (Figure 4D). Puzzlingly, the Phe179Leu
mutant was partially resistant to phosphorylation by CaMKKb,
even up to incubation times of 60 min (data not shown); however,
it is activated 2.7- and 2.8-fold by A769662 and AMP, respec-
tively. As the CaMKKb-treated g1 mutants have similar depen-
dence to A769662 and AMP as wild-type AMPK, with the
exception of Arg171Gln, which still had reduced AMP stimula-
tion, we next determined whether they had different sensitivities
to A769662 and AMP by measuring activation over a range
of concentrations. Two mutants, Leu178Ala and Phe179Leu,
increased the concentration of A769662 required to give half-
Figure 3. Structural Models of b1-CBM and the g1 Subunit
(A) Structural model of b1:CBM (green)/b1:190–272 (blue)/g1:23–326 (red)
based on the S. cerevisiae Snf4/Sip2 complex structure. AMP nucleotides
evident in the structure of the regulatory fragment of mammalian AMPK are
in orange.
(B) Boxed region encompassing the g1 helix a2B is shown in more detail, along
with residues selected for mutation analysis in magenta.Chemistry & Biology 15, 1220–12maximal activation (Figure 4E; see Table S1 available online),
whereas the Arg171Gln and to a lesser extent the Phe175Leu
mutant increased the dose dependence for AMP activation (Fig-
ure 4F; Table S1).
A769662 Specifically Activates AMPK Complexes
Containing the b1 Subunit
Because AMPK subunit isoform composition is important in
determining AMP sensitivity and dependence, we explored
whether activation of AMPK by A769662 is influenced by the
presence of a particular subunit isoform. We expressed all 12abg
combinations of AMPK complex in COS7 cells and measured ac-
tivity in the presence of either 20 mM A769662 or 100 mM AMP.
The fold activation of AMPK by either AMP or A769662 varied
according to the subunit isoform composition. Figure 5A shows
that only AMPK complexes containing the b1 subunit were allo-
sterically activated by A769662 and that complexes containing
the b2 subunit were completely insensitive to the drug. To test
whether activation of AMPK by A769662 is specific to b1 com-
plexes in intact cells, we utilized isolated hepatocytes from b1
null mice and measured AMPK activity in response to A769662
treatment. Mice with a germline deletion of the b1 subunit gene
were generated as described (Figure S1). We confirmed by west-
ern blotting the presence of the b1 subunit in hepatocytes from
wild-type mice but not in those obtained from b1 null mice
(Figure 5B). In the b1 null hepatocytes, a1 and a2 expression
was decreased; however, there was no change in the expression
of the b2 subunit (Figure 5B). Similarly, a1 and a2 activity was de-
creased by 55% and 44% in the b1 null hepatocytes, respec-
tively. Both a complexes were activated in wild-type hepatocytes
treated with 100 mM A769662 or 2 mM AICAR; however, activa-
tion by A769662 was completely abolished in the hepatocytes
lacking theb1 subunit (Figure 5C), supporting our in vitro findings.
AICAR was still able to activate both a1 and a2 complexes from
the b1 null hepatocytes, although to a lesser extent than in wild-
type cells. We also analyzed phosphorylation of acetyl-CoA
carboxylase (ACC), a downstream substrate of AMPK, in re-
sponse to A769662 in the b1 null hepatocytes. Figure 5D shows
that ACC phosphorylation was increased by treatment with either
2 mM AICAR or 100 mM A769662 in the wild-type cells; however,
the effect of A769662 was lost in the b1 null hepatocytes, which is
consistent with the AMPK activity data. Unlike A769662, AICAR
increased ACC phosphorylation in the b1 null hepatocytes,
although to a lower extent than that observed in wild-type cells.
Previous studies have shown that A769662 lowers plasma
glucose in obese mice, and this may be mediated primarily by
activation of AMPK in the liver (Cool et al., 2006); therefore, we
tested whether A769662 decreased glucose production in the
b1 null hepatocytes. Wild-type and b1 null cells were incubated
with either 2 mM AICAR or 100 mM A769662, and glucose pro-
duction was measured at various time points up to 120 min.
Figure 5E shows that basal glucose production in the b1 null
hepatocytes was similar to wild-type cells. Glucose production
in wild-type hepatocytes was decreased by 30% and 90% in re-
sponse to A769662 and AICAR, respectively; however, A769662
lowered glucose production in the b1 null hepatocytes despite
being unable to activate AMPK in these cells (Figure 5F). Our find-
ings indicate that A769662 can also regulate hepatic glucose out-
put by an AMPK-independent mechanism.30, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1223
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Skeletal Muscle
We examined the effect of A769662 and AICAR on AMPK activity
and glucose uptake in extensor digitorum longus (EDL) muscle
isolated from wild-type or b1 null mice. Figure 6A shows that ex-
pression of the a1 subunit was significantly decreased in the b1
null muscle, whereas there was no change in a2 subunit expres-
sion and no compensatory increase in the expression of the b2
subunit. There was no change in a2-associated activity between
wild-type and b1 null muscle; however, a1 activity was de-
creased by 53% (Figure 6B). Incubation with A769662 increased
a1 activity in the wild-type muscle; however, activation was abol-
ished in the b1 null muscle whereas there was no activation of
a2 complexes by A769662 in either wild-type or b1 null muscle.
AICAR activated both a1 and a2 complexes in EDL muscle;
however, activation of a1 was lower in the b1 null muscle but
there was no reduction in the activation of a2 complexes (Fig-
ure 6C). Phosphorylation of ACC was increased in response to
either A769662 or AICAR; however, only the effect of A769662
Figure 4. Activation of AMPK by A769662
Involves the g Subunit
(A) Basal activity of AMPK g1 subunit mutants was
determined using the SAMS assay and by western
blot using anti-phosphothreonine 172 and anti-a1
antibodies. Results are shown as the mean ± SEM
for duplicate experiments.
(B) Activation of g1 subunit mutants was deter-
mined using the SAMS assay in the presence or
absence of 20 mM A769662 or 100 mM AMP. Re-
sults are shown as the mean ± SEM for duplicate
experiments.
(C) Activation of the AMPK a1b1g1 complex with
either 20 mM A769662 or 100 mM AMP measured
at different time points of incubation with CaMKKb
and 200 mM MgATP. AMPK activity was deter-
mined using the SAMS assay and results are
shown as the mean ± SEM for duplicate experi-
ments.
(D) Activation of g1 subunit mutants with either
20 mM A769662 or 100 mM AMP after 10 min incu-
bation with CaMKKb and 200 mM MgATP. AMPK
activity was determined using the SAMS assay
and results are shown as the mean ± SEM for
duplicate experiments.
(E) Activation of g1 subunit mutants measured
over a range of concentrations (0–20 mM) of
A769662. The results were fitted to the following
equation: Activity = Basal + (((Fold Stimulation 3
Basal)  Basal) 3 ([AMP]/(A0.5 + [AMP])).
(F) Same as for (E), except measured over a range
of concentrations (0–100 mM) of AMP. * denotes
significantly different from control (p < 0.02). y de-
notes significantly different from wild-type control
(p < 0.02).
was abolished in the b1 null muscle (Fig-
ure 6D). We next investigated the ability
of A769662 and AICAR to stimulate glu-
cose uptake in both wild-type and b1
null EDL muscle. A769662 was unable
to stimulate glucose transport in either
wild-type or b1 null muscle (Figure 6E). In contrast, AICAR stim-
ulated glucose uptake to the same extent in both wild-type and
b1 null EDL muscle (Figure 6F), suggesting that b1 complexes do
not participate in regulating glucose transport.
DISCUSSION
In this study, we have investigated activation of AMPK by
A769662 and AMP and provided new insights into the mecha-
nisms of allosteric regulation, in particular the role of the b subunit
and the CBM in regulating kinase activity. The b subunits have
divergent N-terminal sequences of poorly defined function, and
the b1 subunit has several posttranslational modifications within
this region including myristoylation at Gly2 and autophosphory-
lation of Ser24/Ser25 (Mitchelhill et al., 1997). The Gly2Ala
mutant had increased activity but A769662 was able to further
activate this mutant, indicating that activation does not involve
simply relieving inhibition caused by the myristoyl group. Dele-
tion of the b1 sequence comprising residues 1–63 also resulted1224 Chemistry & Biology 15, 1220–1230, November 24, 2008 ª2008 Elsevier Ltd All rights reserved
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Regulation of AMPKFigure 5. A769662 Selectively Activates
AMPK Complexes Containing the b1 Sub-
unit
(A) Activity of AMPK complexes was measured us-
ing the SAMS assay with either 20 mM A769662 or
100 mM AMP and shown as the mean ± SEM for
duplicate experiments. # denotes significantly
different from control (p < 0.05).
(B) Western blot analysis of AMPK subunits in
isolated hepatocytes from wild-type and b1 null
mice. Twenty micrograms of extract was analyzed
except for the b2 blot, where 200 mg was used due
to low expression of the b2 subunit.
(C) AMPK a1 or a2 complexes were immunopre-
cipitated from 100 mg of lysate from wild-type or
b1 null hepatocytes incubated with either 100 mM
A769662 or 2 mM AICAR. AMPK activity was
measured in the immunoprecipitates using the
SAMS assay and data are shown as mean ±
SEM (n = 8).
(D) Western blot analysis of ACC phosphorylation
in wild-type and b1 null hepatocytes treated with
either 100 mM A769662 or 2 mM AICAR. Phos-
pho-ACC was detected using a rabbit phospho-
specific-ACC antibody and total ACC was
detected using a streptavidin fluorescent dye
conjugate.
(E) Basal glucose output of wild-type and b1 null
hepatocytes measured at various time points (60,
120, and 180 min). Data are shown as mean ±
SEM (n = 6).
(F) Glucose output in wild-type and b1 null hepato-
cytes after treatment with 100 mM A769662 or
2 mM AICAR. Data are shown as mean glucose
output ± SEM (n = 6) from two independent exper-
iments after 120 min. * denotes significantly differ-
ent from control in the same genotype (p < 0.05). y
denotes significantly different from wild-type
control (p < 0.05).in further activation of AMPK, but again this fragment was still
activated by A769662. Our results indicate that b1 N-terminal
residues either have a direct autoinhibitory role or a tethering
function to secure autoinhibition indirectly. Only truncations re-
moving either half or the complete CBM essentially abolished
activation by A769662, further supporting a role for this domain
in the regulation of AMPK. Importantly, deletion of the CBM
had no effect on activation of AMPK by AMP, indicating that the
loss of A769662 sensitivity was unlikely to be due to gross func-
tional changes in the enzyme. Our findings are in agreement with
Sanders et al., who also reported that the CBM is essential for
A769662-mediated activation using an a1b1(186–270)g1 con-
struct (Sanders et al., 2007a). Their and our findings further rein-
force the view that A769662 binds to a site that is distinct from
the AMP-binding sites. Our data also suggest that it is unlikely
that A769662 binds to either the carbohydrate-binding site or
an alternate site located within the CBM, as we were unable to
detect significant binding of the compound to isolated CBM us-
ing NMR, despite clearly observing changes in the chemical shiftChemistry & Biology 15, 1220–123pattern for maltoheptaose binding to the carbohydrate-binding
site. There was a small change in chemical shift stemming
from Ser144 and Val149 in the presence of A769662; however,
mutation of these residues to alanine had no effect on activation
by the drug (data not shown).
Although the CBM plays a crucial role in activation by
A769662, our studies also suggest a role for the g subunit that
is independent of the three known AMP-binding sites. From our
homology modeling and mutagenesis studies, we have identified
a hydrophobic patch on the g subunit that is situated proximal to
the carbohydrate-binding loop of b1-CBM and showed that this
structural feature is important in regulating phosphorylation of
Thr172 and activation by A769662 and AMP. Mutation of con-
served hydrophobic residues within the patch had varying
effects on allosteric activation in addition to alterations in kinase
activity. Both the Leu178Ala and Phe179Leu mutations showed
decreased basal activity whereas Phe175Tyr, Phe175Leu,
and Phe179Tyr exhibited increased activity, and all of these
effects on kinase activity were associated with altered Thr1720, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1225
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substitution with leucine produced the opposite effect, highlight-
ing the critical nature of this region in switching kinase activity
between active and inactive states. In support of our findings,
mutation of Asn177 in Snf4, which is equivalent to Phe179 in
g1, increases the activity of the SNF1 complex even under high
glucose conditions by increasing phosphorylation of Thr210 (the
residue corresponding to Thr172 in AMPK) (Momcilovic et al.,
2008). The Phe179Leu mutant also led to a 6.6-fold increase in
the half-maximal concentration for activation by A769662,
whereas on the other hand substitution with tyrosine had no
effect on this parameter. This indicates that the Phe179 aromatic
side chain is an important structural element, at least for the
mammalian kinase, and this residue may be located near or
have connectivity with the A769662-binding site. The Leu178Ala
mutant also caused a decrease in AMPK activity as well as caus-
ing a 3.8-fold increase in the half-maximal concentration for
A769662 activation. It is interesting to note that the Leu178Ala
Figure 6. A769662 Does Not Stimulate
Glucose Uptake in Skeletal Muscle
(A) Western blot analysis of AMPK subunits in EDL
muscle (50–80 mg) from wild-type and b1 null mice.
(B) AMPK a1 or a2 complexes were immunopre-
cipitated from 100 mg of EDL muscle lysate from
wild-type or b1 null mice incubated with 100 mM
A769662. AMPK activity was detected in the
immunoprecipitates using the SAMS assay and
data are shown as mean ± SEM (n = 8).
(C) AMPK a1 or a2 complexes were immunopre-
cipitated from 100 mg of EDL muscle lysate from
wild-type or b1 null mice incubated with 2 mM
AICAR. AMPK activity was detected in the immu-
noprecipitates using the SAMS assay and data
are shown as mean ± SEM (n = 8).
(D) Western blot analysis of ACC phosphorylation
in wild-type and b1 null EDL muscle treated with
either 100 mM A769662 or 2 mM AICAR. Phos-
pho-ACC was detected using a rabbit phospho-
specific-ACC antibody and total ACC was
detected using a streptavidin fluorescent dye
conjugate.
(E) Glucose uptake in EDL muscle from wild-type
or b1 null mice incubated with 100 mM A769662.
Data are shown as mean ± SEM (n = 8).
(F) Glucose uptake in EDL muscle from wild-type
or b1 null mice incubated with 2 mM AICAR.
Data are shown as mean ± SEM (n = 8). * denotes
significantly different from basal in the same geno-
type (p < 0.05). y denotes significantly different
from wild-type control (p < 0.05).
and Phe179Leu mutants not only in-
creased the half-maximal concentration
for A769662 but also were the only two
mutants that showed decreased Thr172
phosphorylation and kinase activity. The
low basal activity of the Leu178Ala
mutant may be explained by our finding
that this mutant exhibits some resistance
to phosphorylation by CaMKKb, and it is
possible that this may also apply to
phosphorylation by other upstream kinases such as LKB1. A
possible explanation for the effect of the Phe179Leu mutant is
that A769662 mimics AMP in protecting against Thr172 dephos-
phorylation by phosphatases (Sanders et al., 2007a), so the
decreased level of phosphorylation of the Phe179Leu mutant
may be associated with increased susceptibility to dephosphor-
ylation. Because the Phe179Leu mutant alters the half-maximal
concentration for A769662 but does not have a marked effect
on AMP sensitivity, it may imply that another intracellular metab-
olite besides AMP can protect against AMPK Thr172 dephos-
phorylation and may bind to the A769662 site. The Arg171Gln
and Phe175Leu mutants had striking effects on the half-maximal
concentration for AMP activation without affecting A769662
dose dependence, which was unexpected considering that nei-
ther residue is directly involved in nucleotide binding (Xiao et al.,
2007). Arg171 is located within the putative nucleotide-binding
site that is unoccupied in the mammalian g1 structure; however,
in the recent Schizosaccharomyces pombe core structure, ADP1226 Chemistry & Biology 15, 1220–1230, November 24, 2008 ª2008 Elsevier Ltd All rights reserved
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the b subunit (Jin et al., 2007), and therefore it is possible that
this site becomes occupied by a similar mechanism in the intact
AMPK heterotrimer. It was noticeable that the g mutants with
increased basal activity had lower A769662 and AMP depen-
dence, suggesting that a higher degree of phosphorylation ren-
ders AMPK relatively insensitive to allosteric activation. Indeed,
AMPK that we extensively treated with CaMKKb had reduced
allosteric activation by both A769662 and AMP. Previous studies
have shown that extensively autophosphorylated AMPK is less
AMP dependent (Suter et al., 2006), and this may constitute
a negative feedback mechanism where allosteric regulation of
AMPK is dampened after heightened activity. There is evidence
to suggest that this mechanism operates in vivo, as studies with
ischemic hearts found that AMPK activity increased rapidly with
the onset of ischemia but then decreased even though the AMP/
ATP ratio remained elevated (Beauloye et al., 2001). Interest-
ingly, the fact that increased phosphorylation reduced allosteric
activation by both A769662 and AMP to the same extent lends
further support to the idea that both molecules use a convergent
mechanism to activate AMPK.
Activation of AMPK by AMP is strongly influenced by the g
subunit isoform present in the complex; for example, complexes
containing the g2 subunit have the greatest AMP dependence,
whereas those containing the g3 subunit have the least (Cheung
et al., 2000). This prompted us to test whether activation of AMPK
by A769662 was sensitive to the presence of a particular subunit
isoform, and therefore we analyzed the effects of A769662
against all 12 possible permutations of the AMPK abg complex.
Only b1-containing heterotrimers were activated by A769662,
as all b2 complexes were insensitive irrespective of their a or g
subunit isoform partners. A769662 also selectively activated b1
complexes in intact cells, as activation of both a1 and a2 com-
plexes was abolished in hepatocytes lacking the b1 subunit.
Activation with AICAR was only partially reduced in the b1 null
hepatocytes, demonstrating that AICAR is still able to activate
the remaining b2 complexes. Previous studies using hepatocytes
lacking both a subunit isoforms showed that increased phos-
phorylation of ACC by A769662 is completely dependent on the
expression of the a catalytic subunits (Goransson et al., 2007).
This is supported by our finding that phosphorylation of ACC in
response to A769662 is completely abolished in the b1 null hepa-
tocytes. It is unclear at present why AMPK complexes containing
the b2 subunit are insensitive to A769662, as there is very little se-
quence variation between theb isoforms within the CBM, which is
an essential component for activation by A769662. Intriguingly,
one of the few regions of sequence divergence between b1 and
b2 within the CBM occurs in the sequence surrounding the
Ser108 autophosphorylation site, which has been shown to be
critical for A769662 activation (Sanders et al., 2007a). It has yet
to be determined whether the corresponding residue Ser107 on
theb2 subunit is autophosphorylated, and this may potentially ex-
plain whyb2 complexes are A769662 insensitive. Not only is there
variation in the sequences surrounding Ser107/Ser108, but these
residues also point in opposite directions in the b1/b2 CBM crys-
tal structures; therefore, it is possible that these subtle differences
impact on the ability of Ser107 on b2 to be autophosphorylated.
An important in vivo effect of A769662 is to lower plasma glu-
cose, and it is thought that this is mediated primarily by activationChemistry & Biology 15, 1220–12of AMPK in the liver. Activation of AMPK decreases hepatic glu-
cose production by inhibiting transcription of key enzymes in the
gluconeogenic pathway such as phosphoenolpyruvate kinase
and glucose-6-phosphatase, and mice treated with A769662
have decreased expression of these enzymes (Cool et al.,
2006). It was therefore surprising that A769662 was as effective
at lowering glucose output in the b1 null hepatocytes as in wild-
type cells. There was no alteration in the ability of AICAR to lower
glucose production in the b1 null hepatocytes either, indicating
that A769662 and AICAR may decrease hepatic glucose output
in part by an AMPK-independent mechanism. Interestingly, there
was no change in basal glucose output in the b1 null hepatocytes
despite the fact that both a1 and a2 activity were significantly
decreased. Liver-specific deletion of the a2 subunit leads to
increased hepatic glucose production (Andreelli et al., 2006),
and therefore it was surprising that there was no change in
glucose production in the b1 null cells given that a2 activity was
decreased. It is possible that the remaining a2/b2 complexes
are sufficient to regulate basal and AICAR-stimulated glucose
output. It is well established that AICAR is able to affect other
AMP-sensitive enzymes such as fructose 1,6-bisphosphatase
and glycogen phosphorylase, both of which can alter hepatic
glucose metabolism through gluconeogenesis and glycogenoly-
sis, respectively (Longnus et al., 2003; Vincent et al., 1991).
A769662 has been shown to inhibit fructose 1,6-bisphosphatase
but only at concentrations in the millimolar range (Cool et al.,
2006), and therefore the mechanism underlying the ability of
A769662 to lower glucose output in the b1 null hepatocytes
remains unclear. One interesting possibility is that A769662 acti-
vates phosphofructokinase 1 (PFK1), which plays a key role in
controlling the rate of glycolysis and is activated allosterically
by AMP. Consistent with this idea, activation of PFK1 in liver has
been shown to lower glucose production by increasing the rate of
glycolysis (Wu et al., 2005). It is now beginning to emerge that
A769662 can interfere with other biological pathways unrelated
to AMPK, such as the recently described inhibition of nonproteo-
lytic components of the 26S proteosome by A769662, indicating
the possibility of multiple off-target effects (Moreno et al., 2008).
Activation of AMPK in skeletal muscle is associated with sev-
eral important metabolic responses including stimulation of fatty
acid uptake/oxidation and increased glucose transport, which
provided the impetus to study the effects of A769662 in this tis-
sue. A769662 selectively activated a1 complexes in EDL muscle
whereas there was no activation of a2 complexes; however,
A769662 failed to activate a1 complexes in EDL muscle lacking
the b1 subunit. These findings confirm that selective activation of
b1 complexes by A769662 occurs beyond the liver and includes
skeletal muscle. The expression and activity of only a1 com-
plexes was reduced in the b1 null EDL muscle, indicating that
the b1 subunit likely exists in complex exclusively with the a1
subunit isoform in EDL. A769662 was unable to stimulate glu-
cose uptake either in the presence or absence of the b1 subunit;
however, this may not be that surprising given that the a2 subunit
is essential for upregulation of glucose transport and that
A769662 was unable to activate a2 complexes in EDL (Jorgen-
sen et al., 2004). Activation of a2 complexes and stimulation of
glucose transport by AICAR were unaffected in b1 null muscle
and, taken together with data from a2 null mice, suggest that
AMPK complexes containing a2/b2 subunits are responsible30, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1227
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ingly, recent studies have identified a role for AMPK complexes
containing the a1 subunit in the stimulation of glucose uptake in
response to twitch contraction in skeletal muscle (Jensen et al.,
2008). These findings suggest that activation of a1 complexes by
A769662 and AICAR may not be sufficient to regulate glucose
uptake and that additional stimuli that only occur during twitch
contraction are also required.
SIGNIFICANCE
AMPK is a key regulator of cellular and systemic energy me-
tabolism and is an attractive drug target for treatment of
metabolic diseases, particularly obesity and type 2 diabetes,
and therefore elucidating themechanisms underlying AMPK
regulation may aid the development of better therapeutic
activators of AMPK. We have demonstrated that the thieno-
pyridone A769662 activates AMPK by a novel mechanism
that is independent of the AMP-binding sites but dependent
on the b subunit carbohydrate-binding module and g sub-
unit. Our results provide compelling evidence that the
b subunit of AMPK plays an important role in autoregulation
of the abg complex in addition to its known scaffold function
to anchor the a and g subunits. The revelation that activation
of AMPK by A769662 is b1 specific in one sense limits its use
as a universal AMPK-activating drug but highlights an unex-
pected opportunity of being able to develop isoform specific
activators that can target AMPK in specific tissues such as
skeletal muscle.
EXPERIMENTAL PROCEDURES
Animals
All experimental protocols involving animals were approved by the
St. Vincent’s Hospital Animal Ethics Committee.
Isolation and Culture of Hepatocytes
Isolated hepatocytes from wild-type and b1 null mice were prepared by the
collagenase perfusion method (Seglen, 1976). Briefly, catheters were inserted
into the hepatic portal vein and the livers were perfused with HEPES buffered
saline solution for 10 min, followed by buffer containing collagenase (1.2 mg/
ml) for a further 15 min. Hepatocytes were plated at 106 cells per well in colla-
gen-coated six-well dishes in DMEM supplemented with 10% fetal bovine
serum, glutamine, and antibiotics. The cells were initially cultured for 4 hr in
high insulin, after which the cells were transferred into low-insulin media and
grown overnight. Cells were incubated with either 100 mM A769662 (prepared
by CreaGen) or 2 mM AICAR (Toronto Research Chemicals) for 3 or 1 hr, re-
spectively. Following the treatments, the media were changed and glucose
was measured at various time points using the glucose oxidase/peroxidase-
coupled colorimetric assay (Sigma) and corrected for protein content.
Muscle Incubations and Glucose Uptake
Extensor digitorum longus (EDL) muscles were dissected from anesthetized
mice (6 mg of pentobarbital/100 g body weight) and transferred to incubation
flasks containing 2 ml of essential buffer (Krebs-Henseleit buffer with 2 mM
pyruvate, 8 mM mannitol, 0.1% BSA), gassed with 95% O2/5% CO2, and main-
tained at 30C as previously described (Steinberg et al., 2006). For all
experiments, muscles were preincubated for 15 min with essential buffer, after
which they were incubated with either 100 mM A769662 or 2 mM AICAR for 3 or
1 hr, respectively. 2-deoxy-D-glucose (2DG) uptake was measured over 10 min
by replacing existing incubation buffer with buffer containing 0.50 mCi/ml
2-deoxy-D-[2,6-3H]glucose (GEHealthcare), 1 mM 2-deoxy-D-glucose (Sigma),
and 0.20 mCi/ml D-[1-14C]mannitol (GE Healthcare). Following incubation with1228 Chemistry & Biology 15, 1220–1230, November 24, 2008 ª2002DG, muscles were snap-frozen and lysed in buffer containing 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 50 mM NaF, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, and
1% (v/v) Triton X-100 and radioactivity was quantified by liquid scintillation
counting while remaining lysates were utilized for AMPK activity assays.
Nuclear Magnetic Resonance
AMPK b1-CBM was expressed and isotopically labeled as described previ-
ously. Briefly, b1-CBM was expressed as a His-tag fusion in BL21 Escherichia
coligrown in 1 L of minimalmedia supplemented with 15NH4Cl in a Braun Biostat
fermentor. The b1-CBM was purified by Ni2+ Sepharose and S200 gel-filtration
chromatography (GE Healthcare) and exchanged into NMR buffer (25 mM
Na2HPO4-NaH2PO4 [pH 7.5], 0.02% sodium azide, 10% D2O). NMR spectra
were collected using a Bruker 800 MHz AVANCE spectrometer. For maltohep-
taose (Sigma), 1H-15N heteronuclear single quantum correlation (HSQC) spec-
tra were collected at various titration points ranging from 0 to 10 mM at 800 MHz
at 25C. NMR spectra were collected forb1-CBM in the absence or presence of
5 mM A769662 using the same conditions as for maltoheptaose.
Expression of Recombinant AMPK and Mutant Variants
COS7 cells were grown in DMEM with 10% fetal calf serum at 37C/5% CO2.
Cells were transfected at 60% confluency with 1 mg of the various plasmids ex-
pressing AMPK subunits (pcDNA3 GST-a1, GST-a2, b1, and b2, and pMT2 g1,
g2, and g3) and deletion/point mutants using FuGene 6 (Roche Diagnostics)
according to the manufacturer’s instructions. Transfected cells were har-
vested after 36 hr by washing with ice-cold PBS followed by rapid lysis
in situ using 1 ml of lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl,
50 mM NaF, 1 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1% [v/v] Triton
X-100). Cellular debris was removed by centrifugation and total protein was
determined using the Bradford protein assay (Bio-Rad). AMPK was isolated
from 50 mg of lysate using 10 ml of a 50% slurry of glutathione-Sepharose
(GE Healthcare) pre-equilibrated with lysis buffer, followed by successive
washes in lysis buffer containing 1 M NaCl and finally into assay buffer
(50 mM HEPES [pH 7.4], 1 mM DTT, 0.02% Brij-35). Samples were adjusted
for protein expression by immunoblotting for the a subunit and densitometry.
AMPK Assays
AMPK complexes were purified either by glutathione-Sepharose pull-down
(see above) or immunoprecipitation. For immunoprecipitation experiments,
5 ml of protein A Sepharose (Sigma) complexed with 5 mg of the appropriate
antibody was incubated with 100 mg of lysate for 2 hr at 4C followed by
successive washing with lysis buffer containing 1 M NaCl and finally into assay
buffer, after which activity was determined by phosphorylation of the SAMS
peptide using 100 mM SAMS, 200 mM [g-32P]ATP, and 5 mM MgCl2 in a stan-
dard 25 ml volume assay at 30C. Reactions were terminated after 10 min by
spotting 15 ml onto P81 phosphocellulose paper (Whatman) and washing in
1% phosphoric acid. Radioactivity was quantified by scintillation counting.
l Phosphatase and CaMKKb Treatments
AMPK immobilized on glutathione-Sepharose (5 ml) was incubated with 200 ng
of l phosphatase in 20 ml of dephosphorylation buffer (50 mM HEPES [pH 7.4],
1 mM DTT, 2 mM MnCl2) for 60 min at 30
C, followed by successive washes in
50 mM HEPES (pH 7.4), 1 mM DTT, 1 M NaCl and finally into assay buffer. Fifty
nanograms of CaMKKb and 200 mM ATP, 5 mM MgCl2 was added to a final
volume of 25 ml and incubated at 30C for 10 min. The CaMKKb reaction
was terminated by washing the beads into 50 mM HEPES (pH 7.4), 50 mM
EDTA, 1 mM DTT, followed by successive washes in 50 mM HEPES
(pH 7.4), 1 mM DTT, 1 M NaCl, after which they were washed into assay buffer.
SUPPLEMENTAL DATA
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